Two studies have shown that CRIPSR/Cas9 KO of PRDM1 in CAR-T cells results in improved persistence and overall enhanced tumour control in preclinical models of haematological and solid cancers including leukaemia, melanoma and prostate cancer (141, 142). Here, PRDM1 is linked to neoplasm.